[
  {
    "ts": "2025-12-11T07:47:40+00:00",
    "headline": "HSBC Upgrades AbbVie (ABBV) to Buy, Raises Price Target to $265",
    "summary": "AbbVie Inc. (NYSE:ABBV) is included among the 15 Best Stocks to Buy for the Long Term. On December 10, HSBC increased its price target on AbbVie Inc. (NYSE:ABBV) from $225 to $265 and also upgraded the stock to Buy. Previously, on November 5, Piper Sandler reiterated a Buy rating on ABBV with a $289 price […]",
    "url": "https://finance.yahoo.com/news/hsbc-upgrades-abbvie-abbv-buy-074740751.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "4ce36956-04de-3918-9061-2fbc320571ba",
      "content": {
        "id": "4ce36956-04de-3918-9061-2fbc320571ba",
        "contentType": "STORY",
        "title": "HSBC Upgrades AbbVie (ABBV) to Buy, Raises Price Target to $265",
        "description": "",
        "summary": "AbbVie Inc. (NYSE:ABBV) is included among the 15 Best Stocks to Buy for the Long Term. On December 10, HSBC increased its price target on AbbVie Inc. (NYSE:ABBV) from $225 to $265 and also upgraded the stock to Buy. Previously, on November 5, Piper Sandler reiterated a Buy rating on ABBV with a $289 price […]",
        "pubDate": "2025-12-11T07:47:40Z",
        "displayTime": "2025-12-11T07:47:40Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/84249ecfff511e6ecaf4c7c7fa22aca0",
          "originalWidth": 1920,
          "originalHeight": 1281,
          "caption": "HSBC Upgrades AbbVie (ABBV) to Buy, Raises Price Target to $265",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g_A4z51GYFMmOnX5InXPOw--~B/aD0xMjgxO3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/84249ecfff511e6ecaf4c7c7fa22aca0.cf.webp",
              "width": 1920,
              "height": 1281,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JO7PTUY1uqs5Y0LWdipnYg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/84249ecfff511e6ecaf4c7c7fa22aca0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/hsbc-upgrades-abbvie-abbv-buy-074740751.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/hsbc-upgrades-abbvie-abbv-buy-074740751.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-11T07:30:00+00:00",
    "headline": "10 High-Yielding Dividend Stocks to Buy for 2026",
    "summary": "A stronger economy and Fed rate cuts could provide tailwinds for dividend stocks next year. Consider buying names such as AbbVie, FedEx, and Coca-Cola.",
    "url": "https://www.barrons.com/articles/10-high-yielding-dividend-stocks-buy-2026-97670656?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "5406d42f-1239-3544-8e7a-40ec0d0bab8a",
      "content": {
        "id": "5406d42f-1239-3544-8e7a-40ec0d0bab8a",
        "contentType": "STORY",
        "title": "10 High-Yielding Dividend Stocks to Buy for 2026",
        "description": "",
        "summary": "A stronger economy and Fed rate cuts could provide tailwinds for dividend stocks next year. Consider buying names such as AbbVie, FedEx, and Coca-Cola.",
        "pubDate": "2025-12-11T07:30:00Z",
        "displayTime": "2025-12-11T07:30:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/5406d42f-1239-3544-8e7a-40ec0d0bab8a/10-high-yielding-dividend.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/a651fdb760c3fb55e037f1439a9f4128",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YfGuwoo_VwaFhdGNVeVnvg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/a651fdb760c3fb55e037f1439a9f4128.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0c1asqKru8.vs75RiCGcOw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/a651fdb760c3fb55e037f1439a9f4128.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/10-high-yielding-dividend-stocks-buy-2026-97670656?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "XOM"
            },
            {
              "symbol": "KO"
            },
            {
              "symbol": "FDX"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "PBI"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-11T12:49:00+00:00",
    "headline": "Here's How AbbVie's Oncology Drugs are Aiding Top-line Growth",
    "summary": "ABBV's expanding oncology lineup, spanning new solid tumor drugs and rising Venclexta sales, is helping drive steady top-line growth.",
    "url": "https://finance.yahoo.com/news/heres-abbvies-oncology-drugs-aiding-124900498.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "6b79aa32-9f8b-3905-9def-46d9a2e0d275",
      "content": {
        "id": "6b79aa32-9f8b-3905-9def-46d9a2e0d275",
        "contentType": "STORY",
        "title": "Here's How AbbVie's Oncology Drugs are Aiding Top-line Growth",
        "description": "",
        "summary": "ABBV's expanding oncology lineup, spanning new solid tumor drugs and rising Venclexta sales, is helping drive steady top-line growth.",
        "pubDate": "2025-12-11T12:49:00Z",
        "displayTime": "2025-12-11T12:49:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NXvq4ox9.Dlnga3rarSarw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ut1qVl6so81FolVpx3AkvA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/heres-abbvies-oncology-drugs-aiding-124900498.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/heres-abbvies-oncology-drugs-aiding-124900498.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-11T16:26:00+00:00",
    "headline": "Is AbbVie Stock Too Cheap to Ignore at Today's Price?",
    "summary": "The drugmaker has plenty to offer investors.",
    "url": "https://www.fool.com/investing/2025/12/11/is-abbvie-stock-too-cheap-to-ignore-at-todays-pric/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "7b5e82b8-264c-31d7-8585-d514d0cd8e71",
      "content": {
        "id": "7b5e82b8-264c-31d7-8585-d514d0cd8e71",
        "contentType": "STORY",
        "title": "Is AbbVie Stock Too Cheap to Ignore at Today's Price?",
        "description": "",
        "summary": "The drugmaker has plenty to offer investors.",
        "pubDate": "2025-12-11T16:26:00Z",
        "displayTime": "2025-12-11T16:26:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/22669d3d456fff4e1f2876a4e3d879ec",
          "originalWidth": 1400,
          "originalHeight": 828,
          "caption": "Pharmacist talking to patient.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LFJ6C3vUfnukbn3k9NdZ9Q--~B/aD04Mjg7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/22669d3d456fff4e1f2876a4e3d879ec.cf.webp",
              "width": 1400,
              "height": 828,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SlHxzsCy1QytSjDZ_KyTWQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/22669d3d456fff4e1f2876a4e3d879ec.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/12/11/is-abbvie-stock-too-cheap-to-ignore-at-todays-pric/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-stock-too-cheap-ignore-162600533.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-11T16:19:00+00:00",
    "headline": "$73 Billion Non-Opioid Therapeutics Industry Assessment, 2032 Featuring AbbVie, GlaxoSmithKline, Acorda Therapeutics, Allay Therapeutics, Alnylam Pharmaceuticals and Other Key Players",
    "summary": "The Non-Opioid Therapeutics Market is rapidly expanding due to increased demand for safer pain management Non-Opioid Therapeutics Market Non-Opioid Therapeutics Market Dublin, Dec. 11, 2025 (GLOBE NEWSWIRE) -- The \"Non-Opioid Therapeutics Market - Global Forecast 2025-2032\" has been added to ResearchAndMarkets.com's offering. This market research report focuses on the evolving landscape of the Non-Opioid Therapeutics Market. This sector has grown from USD 40.77 billion in 2024 to USD 43.78 billi",
    "url": "https://finance.yahoo.com/news/73-billion-non-opioid-therapeutics-161900332.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "954ed586-4df2-3c11-8fe8-50b82c5cf468",
      "content": {
        "id": "954ed586-4df2-3c11-8fe8-50b82c5cf468",
        "contentType": "STORY",
        "title": "$73 Billion Non-Opioid Therapeutics Industry Assessment, 2032 Featuring AbbVie, GlaxoSmithKline, Acorda Therapeutics, Allay Therapeutics, Alnylam Pharmaceuticals and Other Key Players",
        "description": "",
        "summary": "The Non-Opioid Therapeutics Market is rapidly expanding due to increased demand for safer pain management Non-Opioid Therapeutics Market Non-Opioid Therapeutics Market Dublin, Dec. 11, 2025 (GLOBE NEWSWIRE) -- The \"Non-Opioid Therapeutics Market - Global Forecast 2025-2032\" has been added to ResearchAndMarkets.com's offering. This market research report focuses on the evolving landscape of the Non-Opioid Therapeutics Market. This sector has grown from USD 40.77 billion in 2024 to USD 43.78 billi",
        "pubDate": "2025-12-11T16:19:00Z",
        "displayTime": "2025-12-11T16:19:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/4f836f1792b9d72b05a0698d690b4b2d",
          "originalWidth": 600,
          "originalHeight": 400,
          "caption": "Non-Opioid Therapeutics Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bPTHrd4OFqLZirKwjqkGoA--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/4f836f1792b9d72b05a0698d690b4b2d.cf.webp",
              "width": 600,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.ISJDA_4F2A0n3R7FtZBVQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/4f836f1792b9d72b05a0698d690b4b2d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/73-billion-non-opioid-therapeutics-161900332.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/73-billion-non-opioid-therapeutics-161900332.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "GSK"
            },
            {
              "symbol": "CDG.MU"
            },
            {
              "symbol": "ALNY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-11T17:45:25+00:00",
    "headline": "Botox maker quietly launches plan to fend off rivals",
    "summary": "Botox has become so synonymous with anti-aging wrinkle treatments that many people use the name the same way they refer to tissues as Kleenex. But the brand power has a downside: Competitors have flooded the market, prices have dropped, and the company behind Botox is now making aggressive moves to ...",
    "url": "https://www.thestreet.com/health/botox-maker-quietly-launches-plan-to-fend-off-rivals",
    "source": "TheStreet",
    "provider": "yfinance",
    "raw": {
      "id": "8bee1763-4a19-3d7a-a6f9-2146ebabe7d1",
      "content": {
        "id": "8bee1763-4a19-3d7a-a6f9-2146ebabe7d1",
        "contentType": "STORY",
        "title": "Botox maker quietly launches plan to fend off rivals",
        "description": "",
        "summary": "Botox has become so synonymous with anti-aging wrinkle treatments that many people use the name the same way they refer to tissues as Kleenex. But the brand power has a downside: Competitors have flooded the market, prices have dropped, and the company behind Botox is now making aggressive moves to ...",
        "pubDate": "2025-12-11T17:45:25Z",
        "displayTime": "2025-12-11T17:45:25Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/thestreet_881/12cae768d8b80187324fe93348f7e62f",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PcdgC8rmk4UHpZpte9PyUQ--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/thestreet_881/12cae768d8b80187324fe93348f7e62f.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/THAwtuy5pvyvWI5rPUL3Jw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/thestreet_881/12cae768d8b80187324fe93348f7e62f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "TheStreet",
          "url": "https://www.thestreet.com/"
        },
        "canonicalUrl": {
          "url": "https://www.thestreet.com/health/botox-maker-quietly-launches-plan-to-fend-off-rivals",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/botox-maker-quietly-launches-plan-174525077.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]